Sanofi: holds over 95% of Kiadis' capital at end of offer
(CercleFinance.com) - At the end of its 308 million euro bid for the Dutch immunotherapy specialist, Sanofi controlled just over 95% of Kiadis' capital, it announced on Tuesday.
After the bid closed yesterday, about 39.9 million shares had been tendered, equivalent to 92.9% of the capital of the specialist in cell-based treatments for infectious diseases.
Taking into account the shares already held directly and indirectly by Sanofi, it now owns 95.03%, a figure that exceeds the threshold for acceptance of the offer, set at 80%.
The offer, which is now declared unconditional, will be reopened from tomorrow until 28 April.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
After the bid closed yesterday, about 39.9 million shares had been tendered, equivalent to 92.9% of the capital of the specialist in cell-based treatments for infectious diseases.
Taking into account the shares already held directly and indirectly by Sanofi, it now owns 95.03%, a figure that exceeds the threshold for acceptance of the offer, set at 80%.
The offer, which is now declared unconditional, will be reopened from tomorrow until 28 April.
Copyright (c) 2021 CercleFinance.com. All rights reserved.